| Nonclinical evaluation of the serum pharmacodynamic biomarkers HGF and shed MET following dosing with the anti-MET monovalent monoclonal antibody onartuzumab. | None |
| Met endosomal signalling: in the right place, at the right time. | None |
| Studies indicate that proto-oncogene proteins c-met (Met) signals post-internalisation from endosomal compartments. | None |
| Targeting the oncogenic Met receptor by antibodies and gene therapy. | None |
| HIF-1 and HIF-2 directly activate the expression of AXL and GAS6/AXL signaling uses lateral activation of the met proto-oncogene (MET) through SRC proto-oncogene nonreceptor tyrosine kinase to maximize cellular invasion. | None |
| Three decades after its discovery the MET oncogene, expressed in normal and cancer stem cells, appears to be a key player in cancer onset and progression. The oncogenic role is sustained both by wild-type MET and by a genetically altered, constitutively activated form. [Review] | None |
| this study suggests that MET mRNA expression assessed by RNA ISH could be useful as a potential marker to identify MET oncogene-addicted GC. | None |
| Data indicate that ascites-mediated phosphorylation of proto-oncogene protein c-met (c-Met) is inhibited by c-Met inhibitor PF04217903. | None |
| Biosynthesis of the protein encoded by the c-met proto-oncogene. | None |
| Meg3 overexpression in insulinoma cells down-regulated the expression of the protooncogene c-met. | None |
| genetic association studies in populations in Ireland and Belgium: Data suggest that frequencies of mutations in MET, BRAF (B-Raf proto-oncogene), and PIK3R1 (phosphoinositide-3-kinase regulatory subunit 1) vary by demographic location. | None |
| Data show that lipocalin 2 (LCN2)-induced migration occurred through activation of the met proto-oncogene protein (Met)/focal adhesion kinase (FAK) cascade. | None |
| Inhibition of ligand-independent constitutive activation of the Met oncogenic receptor by the engineered chemically-modified antibody DN30. | None |
| Data show that monoclonal antibody ARGX-111 inhibits hepatocyte growth factor (HGF)-dependent proto-oncogene protein c-met (MET) activity by competing with HGF for binding to MET. | None |
| Data suggest that targets of RNA interference via MIRN206 (microRNA 206) include MET (proto-oncogene c-met) and EIF4E (eukaryotic initiation factor-4E), in addition to PAX3 (paired box gene 3) and SNX2 (sorting nexin 2). | None |
| Data indicate that Met proto-oncogene protein pathway is an important target for cancer therapy. | None |
| Results indicate that proto-oncogene protein c-MET (MET) expression was significantly associated with MET amplification. | None |
| Data show that silencing of fibroblast growth factor receptors FGFR1 or FGFR2 overcomes resistance to the proto-oncogene proteins c-met (MET) inhibitor. | None |
| Data suggest that proto-oncogene protein c-met (MET )exon 14 deletion (METex14del) is a potential actionable driver mutation in gastrointestinal (GI) malignancies. | None |
| Data indicate that oncogene c-Met was a putative target of microRNA miR-139-5p. | None |